Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation

Recent clinical trials revealed that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce cardiovascular events in type 2 diabetic patients, however, canagliflozin increased limb amputations, an effect not seen with other SGLT2 inhibitors. Since endothelial cell (EC) dysfunction p...

Descripción completa

Detalles Bibliográficos
Autores principales: Behnammanesh, Ghazaleh, Durante, Zane E., Peyton, Kelly J., Martinez-Lemus, Luis A., Brown, Scott M., Bender, Shawn B., Durante, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477081/
https://www.ncbi.nlm.nih.gov/pubmed/31057401
http://dx.doi.org/10.3389/fphar.2019.00362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477081/
https://www.ncbi.nlm.nih.gov/pubmed/31057401
http://dx.doi.org/10.3389/fphar.2019.00362

Ejemplares similares